Pre- and post-natal treatment of hemophagocytic lymphohistiocytosis.
Hemophagocytic lymphohistiocytosis (HLH) is a rare autosomal recessive disorder of infancy and childhood that is invariably fatal if not treated. We report on the first patient to receive post-natal HSCT for HLH after receiving in utero chemotherapy for disease stabilization.
Shah
Ami J
AJ
Division of Research Immunology, Childrens Hospital Los Angeles, California 90027, USA. ashah@chla.usc.edu
Kapoor
Neena
N
Cooper
Robert M
RM
Crooks
Gay M
GM
Lenarsky
Carl
C
Abdel-Azim
Hisham
H
Wu
Shi Qi
SQ
Wilson
Kathy
K
Weinberg
Kenneth I
KI
Parkman
Robertson
R
Kohn
Donald B
DB
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003072:Cognition Disorders; D002658:Developmental Disabilities; D005260:Female; D046128:Fetal Therapies; D005333:Fetus; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007231:Infant, Newborn; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy*; D011247:Pregnancy
D000970:Antineoplastic Agents